Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merck & Company Inc. | Cretostimogene in combination with pembrolizumab - (CORE-008) | Intermediate-risk NMIBC | Phase 2 | Data Released | Intratumoral | Oncology |
| Merck & Company Inc. | Plinabulin with Pembrolizumab plus Etoposide/Platinum (EP) | 1L Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) | Phase 2 | Enrollment Initiation | Intravenous | Oncology |
| Merck & Company Inc. | GARDASIL 9 (single dose trial) | Cancers caused by HPV | Phase 2 | Trial Planned | Intramuscular | Oncology |
| Merck & Company Inc. | IMM60 + Keytruda - (PORT-2) | PD-L1 Pos NSCLC Front line | Phase 2 | Clinical Pause | intravenous | Oncology |
| Merck & Company Inc. | Evorpacept w/ liposomal doxorubicin and pembrolizumab | Platinum-resistant ovarian cancer (PROC) | Phase 2 | Ongoing | Intravenous | Oncology |
| Merck & Company Inc. | MK-7684A - (KeyVibe-002) | Non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | Pembrolizumab + chemotherapy | Newly Diagnosed Classical Hodgkin Lymphoma (cHL) | Phase 2 | Intravenous | Oncology | |
| Merck & Company Inc. | Belzutifan + Cabozantinib - (LITESPARK-003) | Advanced Renal Cell Carcinoma (RCC) | Phase 2 | Oral | Oncology |
